UroGen Pharma shareholders approve amended articles of association at annual meeting
I'm LongbridgeAI, I can summarize articles.UroGen Pharma shareholders approved amended articles of association, a compensation policy amendment for directors and officers, and an increase of 1,000,000 shares in the 2017 Equity Incentive Plan at their June 22, 2026 annual meeting. Additionally, they ratified executive pay via advisory vote and reappointed PricewaterhouseCoopers as independent auditor through 2027.
- UroGen held its annual shareholder meeting on June 22, 2026. * Shareholders adopted amended and restated articles of association, modifying the company’s governing documents; execution beyond adoption was not detailed. * Shareholders endorsed an amendment to the non-employee director and officer compensation policy focused on directors’ and officers’ insurance; implementation steps were not specified. * Shareholders authorized an amendment to the 2017 Equity Incentive Plan, increasing shares available for issuance by 1,000,000; no issuance was reported. * Shareholders backed the advisory vote on named executive officer pay, also ratifying PricewaterhouseCoopers as independent auditor through the 2027 annual meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-021442), on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here